This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
by Zacks Equity Research
If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.
New Strong Sell Stocks for January 23rd
by Zacks Equity Research
ARCO, CAG and GSK have been added to the Zacks Rank #5 (Strong Sell) List on January 23, 2025.
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
by Zacks Equity Research
The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
by Zacks Equity Research
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
by Ekta Bagri
GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results. While the fundamentals look solid, we advise investors to remain on the sidelines at current levels.
How to Play Moderna Stock After the Recent Sales Guidance Cut
by Sundeep Ganoria
Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
by Zacks Equity Research
Moderna, Regeneron, Intellia Sage and GSK are included in this Analyst Blog.
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
by Zacks Equity Research
MRNA and NTLA are down this week after providing financial and strategic updates.
The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular
by Zacks Equity Research
J&J, Eli Lilly, GSK and Intra-Cellular are included in this Analyst Blog.
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
by Kinjel Shah
J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal
by Kinjel Shah
FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.
GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.
Lifecore Biomedical (LFCR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lifecore Biomedical (LFCR) delivered earnings and revenue surprises of 7.41% and 9.64%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock?
Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?
by Sundeep Ganoria
Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
by Ekta Bagri
GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
by Zacks Equity Research
The FDA's nod to IONS' Tryngolza makes it the first approved treatment for FCS. It is also the company's first wholly-owned drug to receive marketing approval.
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
by Zacks Equity Research
GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.
GSK Gets CHMP Nod for Expanded Use of HIV Combo & Jemperli
by Zacks Equity Research
The CHMP recommends marketing approval to GSK's Vocabria plus JNJ's Rekambys for treating HIV-1 infection in adolescents aged 12 years and older.
GILD Obtains Positive CHMP Opinion for Liver Disease Drug
by Zacks Equity Research
The CHMP recommends the approval of Gilead's seladelpar in combination with ursodeoxycholic acid for the treatment of primary biliary cholangitis in adults.
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals
by Zacks Equity Research
Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.
Top Research Reports for Netflix, BP & Constellation Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Netflix, Inc. (NFLX), BP p.l.c. (BP) and Constellation Energy Corporation (CEG), as well as two micro-cap stocks, Tucows Inc. (TCX) and Bridger Aerospace Group Holdings, Inc. (BAER).
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
by Kinjel Shah
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its sales and profits to improve.
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
by Zacks Equity Research
It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news also continued to be in the spotlight.
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals
by Zacks Equity Research
INCY's phase III study, evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer, meets primary and secondary endpoints.
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD
by Zacks Equity Research
The FDA accepts GSK's regulatory filing seeking the expanded use of Nucala in COPD treatment for review.